Company: NKLR
Filing Date: 2025-12-16
Form Type: 424B3
Source: 0001213900-25-121900
Chunk: 103

Company: Terra Innovatum Global N.V.
Filing Date: 2025-12-16
Form: 424B3
Chunk 103
---
 Nuclear Reactors                                                |     | 1/10/2025 |     | 1/10/2026   |     | 1/10/2046  |
| Small and Micro Nuclear                                                                    
 Reactor with Real Time Integrated Safeguard Systems                                        |     | 1/13/2025 |     | 1/13/2026   |     | 1/13/2046  |
| Reactor Vessel Shell                                                                       
 And Integrated Radiological Containment For Small And Micro Nuclear Reactors               |     | 4/20/2025 |     | 4/20/2026   |     | 4/20/2046  |
| Radioisotopes Production                                                                   
 with Nuclear Micro-Reactor                                                                 |     | 4/20/2025 |     | 4/20/2026   |     | 4/20/2046  |

<div align='center'>57</div>

We also engage with international
and local regulatory bodies and existing frameworks to safeguard our innovations across various jurisdictions. However, certain countries
where our reactor components may be manufactured or where our reactor systems may be deployed may offer less robust protection for nuclear
intellectual property compared to the United States or European Union regulatory environments.

Our intellectual property strategy employs
a systematic assessment framework considering:

| — | Critical                                                           
 component manufacturing locations and supply chain considerations; |

| — | Strategic                                                                    
 nuclear technology development pathways across different regulatory regimes; |

| — | Nuclear-specific                                                                     
 intellectual property enforcement mechanisms in target deployment jurisdictions; and |

| — | Commercial                                                                                
 significance relative to established and emerging competitors in specific nuclear markets 
 and regions.                                                                              |

We plan to establish licensing agreements for
certain specialized nuclear technologies from third-party developers and anticipate continued expansion of such arrangements as our reactor
deployment roadmap advances.

Manufacturing and supply chain

We implement a fabless and
contract manufacturing strategy, and expect to contract with key suppliers for all phases of the manufacturing process. We leverage the
expertise of industry-leading suppliers that comply with nuclear quality assurance standards — including 10 CFR 50 Appendix
B — in areas including fabrication, assembly, quality control, reliability testing, and licensing. This approach allows
Terra Innovatum to avoid the significant costs and risks associated with owning and operating manufacturing facilities while enabling
scalability and rapid response to markets changing conditions.

While we plan to directly
procure certain critical raw materials used in our products, such as moderators, fuel,